First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China
Xueru Yin(Key Laboratory of Guangdong Province), Jinlin Hou(Southern Medical University), Guihua Zhuang(Xi'an Jiaotong University), Jidong Jia(National Clinical Research Center for Digestive Diseases), Jing Liu(Tianjin University of Traditional Chinese Medicine), Yuanyuan Liu(Nanfang Hospital), Libo Tao(Sun Yat-sen University), Fuqiang Cui(Peking University), Li Xie(Xi'an Jiaotong University)
Cited by 8
Related Papers
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
|Journal of Clinical and Translational Hepatology|2017|277
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156
Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy
|Clinical Gastroenterology and Hepatology|2020|115